INNOVATIVE BIOANALYSIS
creating solutions | getting results

Efficacy Study Summary of the D6 STERIONZER™ against aerosolized SARS-CoV-2

Project	Aerosol SARS-CoV-2
Product	BIPOLAR NEEDLEPOINT IONIZER
Laboratory Project #	1047
Testing Facility	Innovative Bioanalysis, Inc
Study Dates	04/12/2021 – 08/03/2021
GLP Compliance	All internal SOPs and processes follow GCLP guidelines and recommendations.
Test Substance	SARS-CoV-2 USA-CA1/2020
Description	Provided a D6 compact bipolar needlepoint-ionizing device designed to be integrated into an air movement system such as an HVAC ductsystem, air conditioner or humidifier. The in vitro study evaluates the efficacy of the D6 against aerosolized SARS-CoV-2.
Test Conditions	The study conducted two control tests and 3 viral challenges in a certified Biosafety hood inside a BSL-3 laboratory. The temperature during testing was approximately 73 ±2°F, with a relative humidity of 44%. Air samples were collected after 0, 15 and 30-minute exposure to the operating device.
Test Results	Active SARS-CoV-2 concentrations were observed to have been significantly reduced at the 15-minute and 30-minute time point. After 15 minutes of operation, the trial observed a decrease in the initial viral concentration of 7.02 x 10^6 to an average of 2.97 x 10^6 TCID50/ml and after 30 minutes to an average of 8.86 x 10^4 TCID50/ml.

Exposure Time	*Reduction in %*
15 minutes	57.71
30 minutes	98.74

Conclusion	D6 demonstrated the ability to reduce the concentration of aerosolized SARS-CoV-2 when exposed to a negative and positive ionconcentration.

DocuSigned by:
Kevin Noble
5DF2797BAA78421...

Kevin Noble
Laboratory Director, Innovative Bioanalysis, Inc.

9/7/2021

Date